BioMarin Pharmaceutical Inc.

BMRN | NASDAQ

Price Alert Chart Builder DCF Calculator

$58.18

-$0.33 (-0.56%)

Nov 2, 2026, 1:39 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ALNY Alnylam Pharmaceuticals	N/A
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	N/A
INSM Insmed Incorporated	N/A
IONS Ionis Pharmaceuticals	N/A
PHAR Pharming	N/A
PTCT PTC Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	N/A
TVTX Travere Therapeutics	N/A
VRTX Vertex Pharmaceuticals Incorporated	N/A

Dividend Rankings ➞

Recent News

4 days ago / prnewswire.com
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
7 days ago / prnewswire.com
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
14 days ago / zacks.com
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
20 days ago / zacks.com
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
24 days ago / prnewswire.com
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
28 days ago / prnewswire.com
BioMarin Appoints Cara Bauer as Chief People Officer
1 month ago / cnbc.com
BioMarin reports five-year Pompe disease data showing durable motor function
1 month ago / prnewswire.com
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
1 month ago / seekingalpha.com
BioMarin: Why I See Significant Upside Into 2027
2 months ago / marketbeat.com
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone